Luke is an Associate Scientific Director within the Immuno-oncology team. He earned his MRes and PhD from Imperial College London, where he investigated memory B‑cell repertoire dynamics in response to experimental HIV‑1 vaccination.
He went on to spend six years as a postdoctoral researcher at University College London, investigating adaptive immune responses across a range of contexts including HIV-1 infection, SARS-CoV-2 infection, and haematological malignancies. His work during this time combined deep immunological expertise with advanced assay development and translational research approaches.
Luke joined RoukenBio in 2023. In his current role, he provides scientific leadership and strategic input into the design and execution of bespoke client studies, with a focus on B-cell immunology and immuno-oncology assay development. He works closely with partners to support robust study design, reliable data generation, and clear immunological interpretation
Resources
Insights
22 July 2026
|5 min read
Immune checkpoint blockade has transformed immuno-oncology by turning T cell biology into a powerful therapeutic strategy. This article explores how checkpoint science continues to evolve, from PD-1/PD-L1 therapies to next-generation targets, and why revisiting landmark studies like Barber et al. (2006) remains valuable for linking immune mechanisms to functional outcomes.
Insights
10 July 2026
|5 min read
Discover how precision B cell depletion strategies are advancing immuno-oncology, and how RoukenBio’s translational assay platforms support smarter therapeutic development.
Insights
13 March 2026
|4 min read
In September, our Associate Scientific Director, Luke Muir, and Study Manager Sarah Lemon attended the BSI Innate Immunity Conference 2026 in Manchester on behalf of RoukenBio, with a focus on where the field is heading in inflammasomes, NLRP3 signalling and NETosis. A recurring theme was translation: connecting mechanism to biomarkers, better assay design, and ultimately the next wave of diagnostics and therapeutics.
